EyeD Pharma develops sustained release micro-implants and complex therapeutics for ophthalmic diseases, targeting conditions such as glaucoma and dry eye. Their solutions aim to enhance patient compliance and minimize treatment side effects, addressing the significant challenge of vision loss affecting over a billion people globally.
Funding
$51M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many ophthalmic diseases require frequent and consistent treatment, but patient compliance with eye drops and other traditional methods is often poor. This can lead to disease progression and vision loss, particularly in conditions like glaucoma and dry eye.
Solution
EyeD Pharma develops sustained-release micro-implants and complex therapeutics designed to improve treatment adherence for ophthalmic diseases. These innovative drug delivery systems aim to provide consistent medication levels, reducing the need for frequent administration and minimizing side effects. By ensuring 100% patient compliance, EyeD Pharma's solutions seek to prevent further vision loss and improve the daily quality of life for patients suffering from conditions like glaucoma, dry eye disease, and back-of-the-eye inflammation.
Target Audience
The primary target audience includes patients suffering from ophthalmic diseases such as glaucoma, dry eye disease, and back-of-the-eye inflammation, as well as ophthalmologists and other eye care professionals seeking improved treatment options.
Features
- Sustained-release micro-implants for consistent drug delivery
- Targeted therapies for glaucoma, dry eye disease, and back-of-the-eye inflammation
- Innovative drug delivery system designed for optimal patient compliance
- Formulations using proven active pharmaceutical ingredients (APIs)
- Designed to address unmet medical needs identified by key opinion leaders (KOLs)